Mereo BioPharma (MREO) EBITDA (2023 - 2026)

Mereo BioPharma (MREO) has reported EBITDA for 4 consecutive years, with -$7.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 33.04% year-over-year to -$7.0 million in Q2 2026; TTM through Jun 2026 was -$34.2 million, a 26.21% increase from a year earlier, with the FY2025 full-year figure at -$40.1 million, up 15.32% from the prior year.
• EBITDA was -$7.0 million for Q2 2026 at Mereo BioPharma, up from -$8.8 million in the prior quarter.
• Over five years, EBITDA peaked at -$811000.0 in Q2 2023 and troughed at -$15.3 million in Q4 2024.
• A 4-year average of -$9.4 million and a median of -$9.6 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA plunged 1480.02% in 2024 and jumped 45.07% in 2025, its largest moves.
• Over 4 years, EBITDA stood at -$7.1 million in 2023, then tumbled by 114.3% to -$15.3 million in 2024, then surged by 45.07% to -$8.4 million in 2025, then gained by 16.21% to -$7.0 million in 2026.
• The last three EBITDA figures came in at -$7.0 million (Q2 2026), -$8.8 million (Q1 2026), and -$8.4 million (Q4 2025), per Business Quant data.